What Is Echinocandin B? Definition and What Research Reports

Echinocandin B is a naturally occurring cyclic lipopeptide produced by filamentous fungi. Structurally it consists of a macrocyclic hexapeptide core built largely from non-proteinogenic and hydroxylated amino acids, acylated at one residue with a long-chain fatty acid tail. It is not made by ribosomal translation from a gene-encoded mRNA sequence; instead it is assembled by a multi-domain nonribosomal peptide synthetase (NRPS) together with tailoring enzymes, and the biosynthetic gene cluster responsible was identified and characterised in Emericella rugulosa NRRL 11440 (PMID 22998630). In the published literature the name appears in two main contexts: as a natural-product scaffold within the echinocandin family of fungal lipopeptides, and as a fermentation and biocatalysis target whose lipid side chain can be enzymatically removed to give a deacylated core known as the echinocandin B nucleus (PMID 31696017).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment, or personal health. Nothing here describes or suggests use of any substance in humans.

Definition at a Glance

Where Echinocandin B Comes From

Echinocandin B is a microbial secondary metabolite. Its producing organisms are moulds, and the molecule is recovered from fermentation broth rather than synthesised residue-by-residue on a peptide synthesiser. Researchers reported the identification and characterisation of the echinocandin B biosynthetic gene cluster in Emericella rugulosa NRRL 11440, work that assigned the NRPS and associated tailoring genes responsible for building and decorating the cyclic core (PMID 22998630). Because the echinocandin family overlaps chemically with the pneumocandins, review literature has treated their biosynthesis together and discussed production perspectives across related lipopeptides (PMID 30255232).

Structure and Why Peptide Chemists Cite It

Although the term "peptide" is often associated with linear, ribosomally encoded sequences, echinocandin B illustrates a different branch of peptide chemistry. Its ring is closed, several residues are non-standard, and a fatty acyl chain is appended to the peptide framework — features typical of NRPS products. Two published studies focused specifically on how the unusual proline residues arise: one described the cryptic production of trans-3-hydroxyproline during echinocandin B biosynthesis (PMID 29352089), and a companion biochemical and genetic characterisation examined the fungal proline hydroxylase acting in echinocandin biosynthesis (PMID 29987385). Those reports are frequently cited as examples of how tailoring oxygenases install hydroxyl groups on peptide residues at specific positions.

The echinocandin B nucleus

Removing the fatty-acid tail from echinocandin B yields the free cyclic peptide core, generally called the echinocandin B nucleus. Enzymatic deacylation is the route most often described: one study reported that Streptomyces species could deacylate echinocandin B as a method for producing the echinocandin B nucleus (PMID 31696017). The nucleus is a semisynthetic intermediate concept — the deacylated core can in principle be re-acylated with different side chains — which is why enzymology around this step has received sustained attention in the process-biotechnology literature.

What the Published Literature Reports

Biosynthesis and pathway engineering

Beyond the original cluster characterisation (PMID 22998630), researchers have used the pathway as a platform for making analogues that do not occur naturally. One study reported the production of unnatural tetradeoxy echinocandins through deliberate gene cluster design and heterologous expression, in which biosynthetic genes were reorganised in a host organism to yield a less-hydroxylated scaffold (PMID 36807630). Such work is typically framed as structure–pathway exploration: by omitting or rearranging tailoring steps, the resulting peptide differs in hydroxylation pattern from the wild-type product.

Fermentation conditions and producing strains

A recurring theme is how culture conditions change how much echinocandin B a strain makes. One study examined the effects of lipids and surfactants on fermentation production of echinocandin B by Aspergillus nidulans (PMID 33987908), and a related report examined methyl oleate together with microparticle-enhanced cultivation and their effects on echinocandin B fermentation titer (PMID 32557175). Strain work has followed two directions. Mutagenesis was used to obtain an echinocandin B overproducing Aspergillus nidulans capable of using starch as its main carbon source (PMID 32125248). Separately, researchers reported that disruption of the stcA gene blocked sterigmatocystin biosynthesis and improved echinocandin B production in Aspergillus delacroxii, an approach that removes a competing secondary-metabolite pathway (PMID 31280382).

Deacylase and acylase enzymology

The enzymes that cleave the lipid tail are themselves a research subject. One study reported functional expression of an echinocandin B deacylase from Actinoplanes utahensis in Escherichia coli, addressing the practical difficulty of producing this enzyme in a tractable bacterial host (PMID 34339787). More recently, a marine-derived enzyme was described: the study reported a hadal Streptomyces-derived echinocandin acylase discovered through prioritisation of protein families, a bioinformatics-first discovery strategy applied to deep-sea microbial genomes (PMID 38786603). Together with the Streptomyces deacylation report (PMID 31696017), these papers define the enzymatic toolbox described for converting echinocandin B into its nucleus.

How the Term Is Used in Peptide Research

• As a natural-product class name. "Echinocandin B" designates one specific molecule, while "echinocandins" refers to the wider family of fungal cyclic lipopeptides that includes the pneumocandins discussed in review literature (PMID 30255232).
• As a biosynthesis teaching example. It is cited when explaining NRPS assembly lines and post-assembly hydroxylation of peptide residues (PMID 29987385).
• As a bioprocess target. Papers on carbon source, lipid and surfactant supplementation, and microparticle-enhanced cultivation use titer as their endpoint (PMID 32557175).
• As a biocatalysis substrate. Deacylase and acylase studies use echinocandin B as the substrate whose fatty-acid tail is removed (PMID 34339787).

Safety and Human Outcomes: What Studies Report

The verified literature summarised on this page is microbiological, genetic, and bioprocess research: gene clusters, tailoring enzymes, fermentation parameters, mutant strains, and deacylation biocatalysts. None of these reports were clinical trials, and none described human dosing, human safety endpoints, or adverse events. As a result, no adverse-event profile for echinocandin B in people can be summarised from these sources, and none is implied here. Readers evaluating any approved antifungal medicine should rely on that product's regulatory labelling and a licensed clinician, not on biosynthesis literature.

Limitations of This Entry

This is a definitional glossary stub. It describes what echinocandin B is, where it comes from, and what the cited papers investigated — chiefly biosynthesis and production. Fermentation titers, enzyme kinetics, and analogue structures reported in the individual papers are specific to the strains, hosts, and conditions each study used, and the summaries above deliberately avoid restating numerical values outside those experimental contexts. Terminology in this field also varies: "echinocandin B nucleus," "deacylated echinocandin B," and "echinocandin B core" can all appear for the same deacylation product (PMID 31696017).

References

• Identification and characterization of the echinocandin B biosynthetic gene cluster from Emericella rugulosa NRRL 11440 (Journal of the American Chemical Society, 2012)
• Cryptic Production of trans-3-Hydroxyproline in Echinocandin B Biosynthesis (Applied and Environmental Microbiology, 2018)
• Biochemical and genetic characterization of fungal proline hydroxylase in echinocandin biosynthesis (Applied Microbiology and Biotechnology, 2018)
• Biosynthesis of pneumocandin lipopeptides and perspectives for its production and related echinocandins (Applied Microbiology and Biotechnology, 2018)
• Disruption of stcA blocks sterigmatocystin biosynthesis and improves echinocandin B production in Aspergillus delacroxii (World Journal of Microbiology & Biotechnology, 2019)
• Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus (3 Biotech, 2019)
• Mutagenesis of echinocandin B overproducing Aspergillus nidulans capable of using starch as main carbon source (Preparative Biochemistry & Biotechnology, 2020)
• Effects of methyl oleate and microparticle-enhanced cultivation on echinocandin B fermentation titer (Bioprocess and Biosystems Engineering, 2020)
• Effects of lipids and surfactants on the fermentation production of echinocandin B by Aspergillus nidulans (Journal of Applied Microbiology, 2021)
• Functional expression of an echinocandin B deacylase from Actinoplanes utahensis in Escherichia coli (International Journal of Biological Macromolecules, 2021)
• Unnatural tetradeoxy echinocandins produced by gene cluster design and heterologous expression (Organic & Biomolecular Chemistry, 2023)
• A Hadal Streptomyces-Derived Echinocandin Acylase Discovered through the Prioritization of Protein Families (Marine Drugs, 2024)